Author:
Rennert-May Elissa,Chew Derek,Cannon Kristine,Zhang Zuying,Smith Stephanie,King Teagan,Exner Derek V.,Larios Oscar E.,Leal Jenine
Abstract
Abstract
Background
Cardiac implantable electronic devices (CIED) are being inserted with increasing frequency. Severe surgical site infections (SSI) that occur after device implantation substantially impact patient morbidity and mortality and can result in multiple hospital admissions and repeat surgeries. It is important to understand the costs associated with these infections as well as healthcare utilization. Therefore, we conducted a population-based study in the province of Alberta, Canada to understand the economic burden of these infections.
Methods
A cohort of adult patients in Alberta who had CIEDs inserted or generators replaced between January 1, 2011 and December 31, 2019 was used. A validated algorithm of International Classification of Diseases (ICD) codes to identify complex (deep/organ space) SSIs that occurred within the subsequent year was applied to the cohort. The overall mean 12-month inpatient and outpatient costs for the infection and non-infection groups were assessed. In order to control for variables that may influence costs, propensity score matching was completed and incremental costs between those with and without infection were calculated. As secondary outcomes, number of outpatient visits, hospitalizations and length of stay were assessed.
Results
There were 26,049 procedures performed during our study period, of which 320 (1.23%) resulted in SSIs. In both unadjusted costs and propensity score matched costs the infection group was associated with increased costs. Overall mean cost was $145,312 in the infection group versus $34,264 in the non-infection group. The incremental difference in those with infection versus those without in the propensity score match was $90,620 (Standard deviation $190,185). Approximately 70% of costs were driven by inpatient hospitalizations. Inpatients hospitalizations, length of stay and outpatient visits were all increased in the infection group.
Conclusions
CIED infections are associated with increased costs and are a burden to the healthcare system. This highlights a need to recognize increasing SSI rates and implement measures to minimize infection risk. Further studies should endeavor to apply this work to full economic evaluations to better understand and identify cost-effective infection mitigation strategies.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health
Reference24 articles.
1. Greenspon AJ, Patel JD, Lau E, Edmund L, Ochoa J, Frisch D, et al. 16-Year trends in the Infection burden for pacemakers and implantable cardioverter-defibrillators in the United States: 1993 to 2008. J Am Coll Cardiol. 2011;58(10):1001–6.
2. Sohail MR, Eby EL, Ryan MP, Gunnarsson C, Wright LA, Greenspon AJ. Incidence, treatment intensity, and incremental annual expenditures for patients experiencing a cardiac implantable electronic device Infection. Circ: Arrhythm Electrophysiol. 2016;9(8):e003929.
3. Canadian Institute for Health Information. Implantable medical devices in Canada: Insights into high-volume procedures and associated costs. https://secure.cihi.ca/free_products/implantable-medical-devices-report-en.pdf. Published 2020. Accessed June 15 2023.
4. Dang T, Ngo L, Ali A, Hossain S, Kaambwa B, et al. Healthcare costs associated with early Complications following cardiovascular implantable electronic device implantation. Heart Lung Circ. 2019;28:337.
5. Tarakji KG, Mittal S, Kennergren C, Corey R, Poole J, Stromberg K, et al. Worldwide randomized antibiotic envelope Infection prevention trial (WRAP-IT). Am Heart J. 2016;180:12–21.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献